Literature DB >> 3609124

Interactions between local inflammatory and systemic haematological effects of PAF-acether in the rat.

M A Martins, P M Silva, H C Castro, F Neto, M C Lima, R S Cordeiro, B B Vargaftig.   

Abstract

Intraplantar injections of PAF-acether into the rat paw (0.025-16 micrograms/paw) were followed by a bell-shaped dose-response curve for oedema. In parallel to the ascending phase (0.25-2 micrograms/paw) a significant leukopenia was observed whereas thrombocytopenia, haemoconcentration and leukocytosis were seen during the descending phase (4-16 micrograms/paw) as was also observed after the i.v. injection of PAF-acether. I.v. injections of PAF-acether inhibited dose dependently the oedema induced by PAF-acether itself but were inactive against serotonin. Dexamethasone (0.1 mg/kg) inhibited the PAF-acether-induced thrombocytopenia and haemoconcentration but failed to modify the leukocytosis whereas aspirin (100 mg/kg) and indomethacin (1.0 mg/kg) inhibited only the haemoconcentration. The PAF-acether antagonist 48740 RP blocked the systemic haematological alterations and restored the auto-reduced oedema induced by a high dose of PAF-acether (16 micrograms/paw) but was unable to inhibit the paw oedema induced by PAF-acether. It is suggested that haemoconcentration, thrombocytopenia and leukocytosis are independent phenomena associated with the presence of PAF-acether in the bloodstream, these haematological changes and the local oedema induced by PAF-acether involve distinct mechanisms and the auto-inhibitory property of PAF-acether is not restricted to in vitro situations, but extends to local inflammation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609124     DOI: 10.1016/0014-2999(87)90308-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Effects of PAF and PAF antagonists on the shape of venous endothelial cells in vitro.

Authors:  A M Northover
Journal:  Agents Actions       Date:  1989-08

2.  Therapeutic effects of intranasal tocotrienol-rich fraction on rhinitis symptoms in platelet-activating factor induced allergic rhinitis.

Authors:  Cheryl Wei Ling Teo; Stephanie Jia Ying Png; Yee Wei Ung; Wei Ney Yap
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-13       Impact factor: 3.373

3.  Pharmacological modulation of Paf-induced rat pleurisy and its role in inflammation by zymosan.

Authors:  M A Martins; P M Silva; H C Faria Neto; P T Bozza; P M Dias; M C Lima; R S Cordeiro; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

4.  Role of R-type calcium channels in the response of the perfused arterial and venous mesenteric vasculature of the rat to platelet-activating factor.

Authors:  A Claing; G Bkaily; N Berthiaume; P Sirois; M Rola-Pleszczynski; P D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

Review 5.  Platelet-activating factor in cardiovascular stress situations.

Authors:  R Rabinovici; T L Yue; G Feuerstein
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

6.  Platelet activating factor potentiates rat paw oedema induced by different phlogogen agents.

Authors:  A A Izzo; N Mascolo; M V Di Urno; G Autore; G Di Carlo; F Capasso
Journal:  Agents Actions       Date:  1994-05

7.  Platelet activating factor blocks interkinetic nuclear migration in retinal progenitors through an arrest of the cell cycle at the S/G2 transition.

Authors:  Lucianne Fragel-Madeira; Tamara Meletti; Rafael M Mariante; Robson Q Monteiro; Marcelo Einicker-Lamas; Robson R Bernardo; Angela H Lopes; Rafael Linden
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.